Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Accumulated Depreciation for 3 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 42.78% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $8.5 million, up 42.78%, while the annual FY2025 figure was $8.5 million, 42.78% up from the prior year.
  • Accumulated Depreciation hit $8.5 million in Q4 2025 for Artiva Biotherapeutics, up from $7.8 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $8.5 million in Q4 2025 and bottomed at $3.5 million in Q4 2023.
  • Average Accumulated Depreciation over 3 years is $6.4 million, with a median of $6.5 million recorded in 2025.
  • Year-over-year, Accumulated Depreciation surged 67.7% in 2024 and then soared 42.78% in 2025.
  • Artiva Biotherapeutics' Accumulated Depreciation stood at $3.5 million in 2023, then soared by 67.7% to $5.9 million in 2024, then surged by 42.78% to $8.5 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $8.5 million, $7.8 million, and $7.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.